Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, 12-month, placebo-controlled, pivotal, cross-over study of migalastat in treatment naïve Fabry patients who have an amenable mutation and GI symptoms.

Next Previous
Trial Profile

A Randomized, 12-month, placebo-controlled, pivotal, cross-over study of migalastat in treatment naïve Fabry patients who have an amenable mutation and GI symptoms.

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Migalastat (Primary)
  • Indications Fabry's disease
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 11 Jul 2017 According to an Amicus Therapeutics media release, this additional Phase 3 study previously requested by the Agency to assess Gastrointestinal (GI) symptoms is no longer required prior to an NDA submission.
    • 06 Dec 2016 New trial record
    • 28 Nov 2016 According to an Amicus Therapeutics media release, company is working with FDA to finalize the protocol of this trial and plans to initiate enrollment in 2017, with data expected in 2019. This trial will generate additional data which will support regulatory approval of migalastat for Fabry disease in the USA.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top